Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real-World Multicentre Prospective Study to Determine the Accuracy of the SCORED (SCreening for Occult REnal Disease) Questionnaire for SCreening REnal Risk Early Against Nephropathy in Adult Population in Asia

NCT05866276 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05866276
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05866276 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Real-World Multicentre Prospective Study to Determine the Accuracy of the SCORED (SCreening for Occult REnal Disease) Questionnaire for SCreening REnal Risk Early Against Nephropathy in Adult Population in Asia
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
June 22, 2023
Completion date
May 31, 2024
Enrollment
1,426 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease